


Furthermore, Applicants believe that claims 3-6 also were separated in error, since all of these claims are directed to a method of identifying, in a sample of T cells, T cells that recognize HCMV. Applicants submit that claims 3-6 should be grouped together, and since these claims recite the step of contacting a sample of T cells from a patient with peptides according to the invention, Applicants also submit that these claims should be examined together with the claims of Group IV (claims 7-10). Examination of these claims together, because the recitations in the body of the claims are so similar, would not create any additional burden to the Office if they were searched and examined together. This is particularly true since the Office also has required that the application also be restricted to a single peptide sequence.

In summary, Applicants request that the Office examine claims 3-10 at this time, or at a minimum at least claims 7-10 in the first instance, and examine the claims with respect to all claimed sequences.

Applicants now request examination on the merits and
favorable consideration of the application.

RESPECTFULLY SUBMITTED,					
NAME AND REG. NUMBER	Martha Cassidy Reg. No. 44,066				
SIGNATURE				DATE	7/11/06
Address	Rothwell, Figg, Ernst & Manbeck 1425 K Street, N.W., Suite 800				
City	Washington	State	D.C.	Zip Code	20005
Country	U.S.A.	Telephone	202-783-6040	Fax	202-783-6031

#1332219v1<RFDMS> -1954-437.rr.wpd